

RB
SA
CE

HHC	MA	SA	AF	LIN	ITS
MA	SA	AF	LIN	ITS	
HELSINN HEALTHCARE					
30 MAR. 2000					
HCB	AD	DG	DM	DT	DP
DS	SAM	GNP	GCA	TAS	
HAS	DG	DM	DT	DP	DS



Jeanne Flynn, Pharm.D.
Associate Director, Licensing

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
805.447.1000
Direct Dial 805.447.3390
Fax 805.499.9315
Email jeannef@amgen.com

March 13, 2000

Rachid BenHamza, Ph.D.Chem
Manager, Licensing-Out
Helsinn Healthcare SA
PO Box 357
6915 Pambio-Noranco
Lugano Switzerland

6

Dear Dr. BenHamza,

Thank you very much for forwarding the confidential information on your 5HT3 antagonist, Palonosetron. We were very impressed with the presentation and thoroughness of your package. Our jobs would be much easier if all such packages were as complete, and easy to review. Your information caused us to analyze and explore the anti-emetic market more thoroughly.

Unfortunately, at this point, our group is not interested in continued evaluation of Palonosetron. We agree the longer half-life of Palonosetron could represent a potential clinical advantage. However, at least in the United States, generic 5HT3 antagonists could be available as early as 2006. This, combined with the lack of efficacy of the 5HT3 antagonists against delayed nausea and vomiting, is the basis of our decision.

Thank you again for the opportunity to review the package. We wish you continued success in developing Palonosetron.

Sincerely,

Jeanne Flynn, Pharm.D.
Associate Director
Product Licensing
Amgen

cc:Linda Pullan